A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1

Clinical trial NCT07179640 · RECRUITING

Trial details

NCT number: NCT07179640
Sponsor: Alesta Therapeutics
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Hypophosphatasia (HPP)

Start date: 2025-09-30
Primary completion: 2027-01-01
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.